Current version snapshot

Not FDA-approved↗Safety records↗

Current · version 2: LL-37↗↗

Related names recorded in this version: Cathelicidin LL-37, Ropocamptide, LL37↗

A 37-amino-acid human cathelicidin peptide, also called ropocamptide, tested in small trials in chronic ulcers. FDA lists it among compounding substances that may present significant safety risks.↗↗↗

This immutable URL preserves the current public version.
The canonical profile remains the primary reading view. Read the canonical profile.
Update · November 16, 2026

We added three randomized trials of LL-37 in chronic ulcers, FDA’s advisory committee page listing LL-37 for a meeting before the end of February 2027, and the spelling LL37 that trial registrations use, so that those registrations are matched. 7685

What this version reported

Three small randomized trials in chronic leg and foot ulcers report mixed results; the largest found no significant difference from placebo. FDA states that it lacks sufficient safety information on LL-37 in people. LL-37 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗↗

Organizations named in cited records:
  • U.S. Food and Drug Administration↗↗
  • U.S. Department of Health and Human Services↗

Reader guide in this version

Key takeaway

LL-37 is a 37-amino-acid peptide of the human cathelicidin family, recorded in FDA’s substance registry as cathelicidin LL-37 (human), with the international name ropocamptide.1 It has been tested in small randomized trials in chronic leg and foot ulcers. The largest, in 148 people with venous leg ulcers, found no significant difference in healing compared with placebo.6,7,8 FDA lists cathelicidin LL-37 among compounding substances that may present significant safety risks, stating that it lacks enough safety information to know whether LL-37 would cause harm in people, and noting nonclinical findings of harm to male reproduction and tumor promotion.2 No FDA approval is reported in the sources reviewed here, and LL-37 is not among the six peptides in HHS’s October 2026 draft policy.2,4

At a glance

What it is
A 37-amino-acid peptide beginning with two leucines (hence LL-37), recorded as human cathelicidin LL-37 and ropocamptide in FDA’s substance registry.1
FDA status
No FDA approval is reported in the sources reviewed here. FDA lists cathelicidin LL-37 among bulk substances whose compounding nominations were withdrawn and that may present significant safety risks.2
Human evidence
Three small randomized, placebo-controlled trials in chronic ulcers, with mixed results: two reported faster healing, and the largest found no significant difference overall.6,7,8
Evidence strength
Smaller controlled human trials

What is LL-37?

LL-37 is a peptide of 37 amino acids, starting with two leucines, that FDA’s substance registry records as cathelicidin LL-37 (human) and under the international nonproprietary name ropocamptide.1

The company behind the venous leg ulcer trials states that it is developing LL-37 under the name ropocamptide.7

How is LL-37 thought to work?

The authors of the 2023 diabetic foot ulcer trial describe LL-37 as having antimicrobial properties and as promoting new blood vessel formation and the movement and growth of skin cells.8

Those are researchers’ descriptions of proposed actions. The FDA sources reviewed here do not describe how LL-37 works, and report nonclinical findings on its possible harms.2,8

What do human studies show?

In a 2014 first-in-human trial in 34 people with hard-to-heal venous leg ulcers, the two lower LL-37 strengths were reported to speed healing compared with placebo over four weeks, while the highest strength showed no difference. The authors reported no safety concerns.6

HEAL LL-37, a larger randomized, placebo-controlled trial in 148 people with venous leg ulcers published in 2021, did not find a significant difference in healing between LL-37 and placebo in the whole study population. An after-the-fact analysis suggested a benefit in people with large ulcers, which the authors say needs a properly powered trial.7

In a 2023 randomized, double-blind trial in 25 people with mildly infected diabetic foot ulcers, granulation, a measure of wound healing, increased more with LL-37 than with placebo, but inflammation markers and bacterial counts did not fall more.8

ClinicalTrials.gov also lists a study of LL37 in melanoma (NCT02225366), listed as Phase 1/Phase 2 and completed in its December 9, 2021 record. A registration lists what was planned; it does not show whether LL-37 worked.9

FDA states that it lacks sufficient safety-related information on cathelicidin LL-37 to know whether it would cause harm when given to humans.2

What the evidence base contains

  • Controlled human trial HEAL LL-37: a double-blind, randomized, placebo-controlled Phase 2b trial in 148 people with hard-to-heal venous leg ulcers, alongside compression therapy. It found no significant improvement in healing in the whole study population.7
  • Controlled human trial A first-in-human trial in 34 people with hard-to-heal venous leg ulcers, with a four-week randomized, double-blind comparison of three LL-37 strengths against placebo.6
  • Controlled human trial A randomized, double-blind trial in 25 people with mildly infected diabetic foot ulcers (13 given LL-37, 12 placebo) for four weeks.8
  • Animal or laboratory research Nonclinical research findings, cited by FDA, suggesting harmful effects on male reproduction and that LL-37 can promote tumor growth in some tissues.2

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is LL-37 FDA-approved?

None of the sources reviewed here reports an approval of LL-37 by FDA.1,2

FDA’s compounding safety-risk page, current as of April 22, 2026, lists cathelicidin LL-37 among bulk substances previously in category 2 whose nominations were withdrawn, citing possible immune reactions and characterization problems.2

FDA’s page for the next meeting of its Pharmacy Compounding Advisory Committee, current as of April 15, 2026, lists cathelicidin LL-37 among substances the committee will discuss for the 503A bulks list at a meeting before the end of February 2027, with the date not yet set.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. LL-37 is not among them.3,4

Timeline

  1. Results of a first-in-human randomized trial of LL-37 in venous leg ulcers are published.6
  2. Results of the HEAL LL-37 trial in venous leg ulcers are published, finding no significant difference from placebo overall.7
  3. Results of a randomized trial of LL-37 in diabetic foot ulcers are published.8
  4. FDA’s advisory committee page lists cathelicidin LL-37 for discussion at a meeting before the end of February 2027.5
  5. FDA’s compounding safety-risk page, as last updated, lists cathelicidin LL-37 among withdrawn nominations with safety concerns.2

What is still unknown?

Whether it helps ulcers heal: the largest trial reviewed here found no significant difference from placebo, and the others were small.6,7,8

Whether it is safe in people, which FDA states it lacks the information to judge, and whether the reproductive and tumor-promoting effects seen in nonclinical research apply to people.2

What FDA’s advisory committee will conclude; its page did not give a meeting date.5

Sources for this version

  1. 1
    Ropocamptide (cathelicidin LL-37, human) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  2. 2
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  3. 3
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  4. 4
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  5. 5
    Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027) · content current as of April 15, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  6. 6
    Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial (2014) · PMID 25041740 ↗

    Wound Repair and Regeneration · Official source · Source checked November 16, 2026

  7. 7
    Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial (2021) · PMID 34687253 ↗

    Wound Repair and Regeneration · Official source · Source checked November 16, 2026

  8. 8
    Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial (2023) · PMID 37480520 ↗

    Archives of Dermatological Research · Official source · Source checked November 16, 2026

  9. 9
    ClinicalTrials.gov record NCT02225366 · retained source version 2021-12-09:d146b413ecf538257bf7086de94ac2024ae7cdada6f1e2c17c5051fba93f7d5c ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026